Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer.
Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, Waller CF, Thomas M, Eggert J, Schmid-Bindert G, Hoiczyk M, Christoph DC, Kimmich M, Deuß B, Seifert S, Held S, Schuler M, Herold T, Breitenbuecher F, Eberhardt WEE. Metzenmacher M, et al. Among authors: breitenbuecher f. Ther Adv Med Oncol. 2021 Mar 9;13:1758835921996506. doi: 10.1177/1758835921996506. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34104223 Free PMC article.
Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.
Breitenbuecher F, Hoffarth S, Worm K, Cortes-Incio D, Gauler TC, Köhler J, Herold T, Schmid KW, Freitag L, Kasper S, Schuler M. Breitenbuecher F, et al. PLoS One. 2014 Jan 21;9(1):e85350. doi: 10.1371/journal.pone.0085350. eCollection 2014. PLoS One. 2014. PMID: 24465542 Free PMC article. Clinical Trial.
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.
Köhler J, Schuler M, Gauler TC, Nöpel-Dünnebacke S, Ahrens M, Hoffmann AC, Kasper S, Nensa F, Gomez B, Hahnemann M, Breitenbuecher F, Cheufou D, Özkan F, Darwiche K, Hoiczyk M, Reis H, Welter S, Eberhardt WE, Eisenacher M, Teschler H, Stamatis G, Schmiegel W, Hahn SA, Baraniskin A. Köhler J, et al. Among authors: breitenbuecher f. J Cancer Res Clin Oncol. 2016 Apr;142(4):795-805. doi: 10.1007/s00432-015-2095-y. Epub 2015 Dec 19. J Cancer Res Clin Oncol. 2016. PMID: 26687686
Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma.
Oezkan F, Herold T, Darwiche K, Eberhardt WEE, Worm K, Christoph DC, Wiesweg M, Freitag L, Schmid KW, Theegarten D, Hager T, Koenig MJ, He K, Taube C, Schuler M, Breitenbuecher F. Oezkan F, et al. Among authors: breitenbuecher f. Clin Lung Cancer. 2018 Nov;19(6):e879-e884. doi: 10.1016/j.cllc.2018.08.016. Epub 2018 Aug 22. Clin Lung Cancer. 2018. PMID: 30206042
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Breitenbuecher F, von Pawel J, Sebastian M, Kortsik C, Ting S, Kasper S, Wohlschläger J, Worm K, Morresi-Hauf A, Schad A, Westerwick D, Wehler B, Werner M, Munzert G, Gaschler-Markefski B, Schmid KW, Schuler M. Breitenbuecher F, et al. Oncol Res Treat. 2017;40(7-8):435-439. doi: 10.1159/000475503. Epub 2017 Jun 20. Oncol Res Treat. 2017. PMID: 28628916 Clinical Trial.
30 results